English

The “Aging With HIV Cheat Sheet” provides practical, research-informed guidance for people living with HIV who are growing older — reflecting that many people with HIV now live well into middle age and beyond. It recognizes that as people with HIV age, their health needs evolve — combining general aging challenges with HIV-specific risks. 
Why aging with HIV matters more now:
•    In the U.S., more than half of people living with HIV are now aged 50 or older.

This educational video focuses on syphilis as an emerging threat to the health of birthing people and their infants. It provides guidance for prenatal nurses on understanding syphilis, interpreting diagnostic tests, educating patients, and implementing treatment strategies. The video emphasizes the importance of early detection, effective treatment with penicillin, partner testing, and follow-up testing to prevent serious complications such as stillbirth, congenital infection, and long-term developmental issues in newborns.

This article provides a comprehensive overview of pre-exposure prophylaxis (PrEP), a highly effective HIV prevention medication for people who are HIV-negative and at increased risk of acquiring the virus. It explains that when taken as prescribed, PrEP reduces HIV transmission risk by about 99%, making the chance of contracting HIV from someone correctly using PrEP extremely low.

This report provides an overview of high-risk HIV behaviors among women ages 18–44 in the United States, based on national surveillance data from the Behavioral Risk Factor Surveillance System (BRFSS). High-risk behaviors include injecting non-prescribed drugs, receiving treatment for a sexually transmitted infection, and exchanging sex for money or drugs within the past year. These behaviors are key indicators of HIV vulnerability and often reflect broader social and structural factors such as access to health care, substance use patterns, and economic instability.

This article reviews key clinical and public health considerations surrounding recent tuberculosis (TB) cases reported in Maine, North Carolina, and California. Although TB remains relatively rare in the United States, it continues to cause more than 1 million deaths annually worldwide and poses ongoing risks, particularly for individuals with weakened immune systems or those who live or work in congregate settings.

This webinar session, Tuberculosis: A Disease Neglected, Misunderstood, but Deadly, provides a comprehensive overview of TB’s microbiology, pathophysiology, and current epidemiology, along with effective strategies for public health prevention and clinical management. Facilitated by Gavin Harris, MD (Emory University), the program features didactic instruction from Marcos C.

his webinar session features a case-based discussion on the management of tuberculosis in alignment with the 2025 ATS/CDC/ERS/IDSA Clinical Practice Guidelines. Lahari Tumuluri, MD (Tulane University), will present two TB cases illustrating the application of these guidelines. Jussi Saukkonen, MD (Boston University), and Charles Daley, MD (National Jewish), will review the guideline development process, supporting evidence, and practical implications for treating drug-sensitive and drug-resistant TB, drawing on real-world clinical experience.

The webinar is to enhance community medical providers’ awareness of latent tuberculosis infection (LTBI). A brief overview of latent tuberculosis vs. active tuberculosis is given along with the most recent numbers of TB cases in NYS and CDC estimates of those with LTBI. It encourages community providers to assess their patients for TB risk factors, then test and treat them for LTBI as indicated.

This fact sheet discusses how research from the University of California San Diego and published in Clinical Infectious Diseases, estimates the hepatitis A vaccination coverage needed to prevent outbreaks among people who inject drugs (PWID). Analyzing surveillance data from 16 states with recent hepatitis A outbreaks linked to PWID, the study found that vaccination coverage of at least 80% may be necessary to reliably achieve herd immunity—though some states, such as West Virginia, may require higher levels.

This webinar features a presentation from the March 2024 Conference on Retroviruses and Opportunistic Infections (CROI), where Dr. Patrick Sullivan—AIDSVu Principal Scientist and Professor at Emory University—presented the oral abstract, “Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012–2021.” Using real-world data on PrEP coverage, Dr. Sullivan’s study found that states with a higher proportion of people with PrEP indications who were using PrEP experienced steeper declines in new HIV diagnoses over the past decade.